Oracle (ORCL) PT Raised to $147 at Barclays, 'RPO Strength And Capex Ramp Point To Better Times Ahead'

Barclays analyst Raimo Lenschow raised the price target on Oracle (NYSE: ORCL) to $147.00 (from $140.00) while maintaining a Overweight rating.

The analyst comments "Q3 in itself was a solid quarter for ORCL with slightly better application and infrastructure growth. However, the items investors will more likely focus on are higher Capex this quarter and expected next FY ($2.1bn for Q3 underlying, $10bn for FY25) along with healthy RPO growth as this suggests higher cloud growth ahead."

You May Also Be Interested In

• X-Energy Inc (XE) PT Lowered to $34 at UBS
• Oruka Therapeutics (ORKA) PT Raised to $130 at UBS as Stock Undervalued
• Kura Sushi USA Inc. (KRUS) PT Lowered to $70 at DA Davidson Ahead of Q3 Results